Data Supplement

Cabozantinib for previously-treated radioiodine-refractory differentiated thyroid cancer:

Updated results from the phase 3 COSMIC-311 trial

Marcia S. Brose, Bruce Robinson, Steven I. Sherman, Barbara Jarzab, Chia-Chi Lin, Fernanda

Vaisman, Ana O. Hoff, Erika Hitre, Daniel W. Bowles, Suvajit Sen, Jennifer W. Oliver, Kamalika

Banerjee, Bhumsuk Keam, Jaume Capdevila

Table of Contents	
TABLE S1. Subsequent Therapy	. 2
TABLE S2. Treatment Exposure and Dose Modification (Safety Population)	. 3
Figure S1. Waterfall plot for maximum percentage of tumor reduction from baseline in target lesions	5
for individual patients	. 4

TABLE S1. Subsequent Therapy^a

	Cabozantinib (n = 170)	Placebo (n = 88)	
Systemic nonradiation anticancer therapy, No. (%)	19 (11)	10 (11)	
Protein kinase inhibitors ^b	16 (9)	9 (10)	
Lenvatinib	7 (4)	4 (5)	
Cabozantinib	2 (1)	3 (3)	
Dabrafenib	2 (1)	1 (1)	
Sunitinib	2 (1)	0	
Trametinib	2 (1)	1 (1)	
Axitinib	1 (1)	0	
Pazopanib	1 (1)	0	
Vemurafenib	1 (1)	0	
Repotrectinib	0	1 (1)	

^aReceipt of open-label cabozantinib was not considered a subsequent therapy. ^bPatients who received >1 protein kinase inhibitor were counted once.


Cabozantinib	Placebo	
(n = 170)	(n = 88)	
6.0 (0.2–18.8)	2.6 (0.2–15.2)	
39.5 (9.5–60.0)	59.9 (18.4–68.3)	
136 (80)	24 (27)	
120 (71)	24 (27)	
12.5 (1.0–112.0)	13.3 (1.0–63.0)	
114 (67)	3 (3)	
114 (67)	3 (3)	
54 (32)	0	
57.0 (14.0–510.0)	85.0 (36.0–153.0)	
127.5 (28.0–472.0)	NA	
15 (9) ^ь	0	
10 (6)	0	
	(n = 170) 6.0 (0.2–18.8) 39.5 (9.5–60.0) 136 (80) 120 (71) 12.5 (1.0–112.0) 114 (67) 114 (67) 54 (32) 57.0 (14.0–510.0) 127.5 (28.0–472.0) 15 (9) ^b	

TABLE S2. Treatment Exp	nosure and Dose I	Modification ((Safety Po	nulation)
TADLE JZ. ITEALITICITUEN	posule and pose i	wouldentation	Jaretyru	pulation

Abbreviations: mo, months; NA, not applicable; No., number.

^aUnrelated to differentiated thyroid cancer. ^bAdverse events leading to discontinuation of cabozantinib (patients could have experienced more than 1 event): fatigue (3), diarrhea (2), arthralgia (1), abdominal pain (1), cardiorespiratory arrest (1), diverticular perforation (1), hypercalcemia (1), large-intestine perforation (1), increased liver function test (1), myalgia (1), myelodysplastic syndrome (1), neutrophil count decreased (1), pain (1), polyneuropathy (1), posterior reversible encephalopathy syndrome (1), proteinuria (1), renal impairment (1), stomatitis (1), stress cardiomyopathy (1), thrombocytopenia (1), urinary retention (1), weight decreased (1).

Figure S1. Waterfall plot for maximum percentage of tumor reduction from baseline in target lesions for individual patients. (A) Cabozantinib group. (B) Placebo group. Tumor response was assessed with Response Evaluation Criteria in Solid Tumors version 1.1 by blinded independent radiology committee. The waterfall plots show the maximum percentage of reduction or minimum increase from baseline in sum of diameters of target lesions before progressive disease or initiation of any nonprotocol anticancer medication. Only patients with at least 1 baseline and postbaseline assessment are shown. Any reduction in the sum of diameter in target lesion was observed in 115/144 (80%) evaluable patients assigned to cabozantinib and 18/76 (24%) assigned to placebo.



Abbreviation: SoD, sum of diameters.